2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-124796
    Qstatin 902688-24-8 ≥98.0%
    QStatin is a potent and selective inhibitor of SmcR (V. harveyi LuxR homologue) with an EC50 of 208.9 nM, binding tightly to SmcR and changes the flexibility of the protein, thereby altering its transcription regulatory activity. QStatin shows pan-QS (Vibrio quorum sensing) inhibitor activity in diverse Vibrio species and attenuates their virulence in an aquatic host. QStatin may be a sustainable antivibriosis agent useful in aquacultures.
    Qstatin
  • HY-124801
    ABMA 332108-65-3 98.68%
    ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity.
    ABMA
  • HY-125747
    Actinomycin X2 18865-48-0 ≥98.0%
    Actinomycin X2 (Actinomycin V)，produced by many Streptomyces sp.，shows strong inhibition of MRSA with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection.
    Actinomycin X2
  • HY-126113
    KIN101 610753-87-2 99.44%
    KIN101 is a potent RNA viral inhibitor with IC50s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.
    KIN101
  • HY-129405
    N-(Ketocaproyl)-DL-homoserine lactone 76924-95-3 98.45%
    N-(Ketocaproyl)-DL-homoserine lactone is a natural, very active ligand of LuxR. N-(Ketocaproyl)-DL-homoserine lactone is a quorum sensing (QS) autoinducer.
    N-(Ketocaproyl)-DL-homoserine lactone
  • HY-129578
    Asperphenamate 63631-36-7 ≥98.0%
    Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC50 values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively.
    Asperphenamate
  • HY-133154
    Carboxyaminoimidazole ribotide 6001-14-5 98.31%
    Carboxyaminoimidazole ribotide (CAIR) is a metabolite of E. coli. Carboxyaminoimidazole ribotide can be used to detect distinctive features of E. coli PurE active site and synthesis fungal de novo purine.
    Carboxyaminoimidazole ribotide
  • HY-135659
    BSH-IN-1 2553217-91-5 ≥98.0%
    BSH-IN-1 is a potent and covalent inhibitor of gut bacterial recombinant bile salt hydrolases (BSHs) with IC50s of 108 nM and 427 nM for B. longum BSH (Gram positive) and B. theta BSH (Gram negative), respectively.
    BSH-IN-1
  • HY-135813
    LtaS-IN-1 877950-01-1
    LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.
    LtaS-IN-1
  • HY-136637
    NPD-001 469863-16-9 99.50%
    NPD-001 is a potent Trypanosoma brucei phosphodiesterases TbrPDEB1 and TbrPDEB2 inhibitor, with IC50 values of 4 and 3 nM, respectively. NPD-001 also inhibits human PDEs (phosphodiesterases). NPD-001 shows good anti trypanosomal activity, with an IC50 of 80 nM.
    NPD-001
  • HY-13735C
    l-Atabrine dihydrochloride 56100-42-6 98.35%
    l-Atabrine dihydrochloride is a less active enantiomer of quinacrine which displays antiprion activity.
    l-Atabrine dihydrochloride
  • HY-13986A
    (R)-Merimepodib 2748420-50-8
    (R)-Merimepodib is the isomer of Merimepodib (HY-13986), and can be used as an experimental control. Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
    (R)-Merimepodib
  • HY-14273S
    Isavuconazole-d4 1346598-58-0 99.88%
    Isavuconazole-d4 is a deuterium labeled Isavuconazole (BAL-4815). Isavuconazole is a triazole proagent with antifungal activity against yeasts, molds, and dimorphic fungi[1].
    Isavuconazole-d4
  • HY-143899
    FBA-IN-1 2605897-57-0 98.79%
    FBA-IN-1 (compound 2a11) is a first-in-class, covalent and allosteric inhibitor of fructose-1,6-bisphosphate aldolase from Candida albicans (CaFBA). FBA-IN-1 inhibits the growth of Azole-resistant strains 103 with the MIC80 of 1 μg/mL.
    FBA-IN-1
  • HY-145079
    Bunamidine hydrochloride 1055-55-6 99.79%
    Bunamidine hydrochloride is a veterinary anti-platyhelmintic agent used for Echinococcus granulosus and Taenia hydatigena.
    Bunamidine hydrochloride
  • HY-145307
    DATPT 2891582-75-3 99.50%
    DATPT is a 12WLVSKF17 peptide-mimetic molecule. DATPT blocks the SNX9-p47phox interaction in the endosome and suppresses reactive oxygen species and inflammatory cytokine production. DATPT with anti-inflammatory and antibacterial functions has the potential for the research of sepsis.
    DATPT
  • HY-148836
    c-Myc inhibitor 6 2768765-58-6 98.04%
    c-Myc inhibitor 6 (compound A102) is a c-Myc inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection.
    c-Myc inhibitor 6
  • HY-15232B
    Tenofovir alafenamide hemifumarate 1392275-56-7 ≥99.0%
    Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
    Tenofovir alafenamide hemifumarate
  • HY-153335
    Enpp-1-IN-16 2289739-47-3 99.11%
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders.
    Enpp-1-IN-16
  • HY-160922
    BAY 249716 696628-24-7 99.03%
    BAY 249716 stabilizes all three p53 protein variants. BAY 249716 also has antitubercular activity (IC90: <0.10 μg/mL for Tuberculosis).
    BAY 249716
Cat. No. Product Name / Synonyms Application Reactivity